Title : A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.

Pub. Date : 2011 Oct

PMID : 20127139






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
2 OBJECTIVES: To assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with metastatic colorectal cancer who had failed one or two previous chemotherapeutic regimens that included oxaliplatin and/or irinotecan. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens